These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7438105)

  • 1. Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide.
    Bryant BM; Jarman M; Baker MH; Smith IE; Smyth JF
    Cancer Res; 1980 Dec; 40(12):4734-8. PubMed ID: 7438105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
    Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
    Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
    Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
    Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of phosphorodiamidic acid mustard as a human metabolite of cyclop hosphamide.
    Fenselau C; Kan MN; Billets S; Colvin M
    Cancer Res; 1975 Jun; 35(6):1453-7. PubMed ID: 1131817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
    Bryant BM; Jarman M; Ford HT; Smith IE
    Lancet; 1980 Sep; 2(8196):657-9. PubMed ID: 6106781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the metabolism of isopnosphamide (NSC-109724) in man.
    Norpoth K
    Cancer Treat Rep; 1976 Apr; 60(4):437-43. PubMed ID: 1277219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice.
    Struck RF; McCain DM; Tendian SW; Tillery KH
    Cancer Chemother Pharmacol; 1997; 40(1):57-9. PubMed ID: 9137530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.
    Lind MJ; Roberts HL; Thatcher N; Idle JR
    Cancer Chemother Pharmacol; 1990; 26(2):105-11. PubMed ID: 2347037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
    Low JE; Borch RF; Sladek NE
    Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkylating properties of phosphoramide mustard.
    Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
    Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide and iphosphoramide mustard in plasma by gas chromatography-mass spectrometry.
    Wang JJ; Chan KK
    J Chromatogr B Biomed Appl; 1995 Dec; 674(2):205-17. PubMed ID: 8788150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electron-capture--gas chromatographic analysis of ifosfamide in human plasma and urine.
    Holdiness MR; Morgan LR
    J Chromatogr; 1983 Jul; 275(2):432-5. PubMed ID: 6619250
    [No Abstract]   [Full Text] [Related]  

  • 14. Embryotoxicity of phenyl ketone analogs of cyclophosphamide.
    Hales BF; Ludeman SM; Boyd VL
    Teratology; 1989 Jan; 39(1):31-7. PubMed ID: 2718138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys.
    Arndt CA; Balis FM; McCully CL; Colvin OM; Poplack DG
    Cancer Res; 1988 Apr; 48(8):2113-5. PubMed ID: 3349482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
    Chang TK; Waxman DJ
    Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
    Chan KK; Hong PS; Tutsch K; Trump DL
    Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
    Jardine I; Brundrett R; Colvin M; Fenselau C
    Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine.
    Kaijser GP; Beijnen JH; Bult A; Wiese G; de Kraker J; Keizer HJ; Underberg WJ
    J Chromatogr; 1992 Dec; 583(2):175-82. PubMed ID: 1478981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of phosphoramide mustard/DNA adducts using tandem mass spectrometry.
    Cushnir JR; Naylor S; Lamb JH; Farmer PB; Brown NA; Mirkes PE
    Rapid Commun Mass Spectrom; 1990 Oct; 4(10):410-4. PubMed ID: 2134189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.